Relapsed or refractory central nervous system lymphoma successfully treated by glofitamab combined with lenalidomide
{{output}}
Background: Central nervous system lymphoma (CNSL) is rare and aggressive, which has high rates of recurrence and fatality. At present, there does not exist any standard treatment for the relapsed/refractory (R/R) CNSL. ... ...
